Novel platinum(IV) complexes that are targeted to and trapped by tumours and tumour cells

铂配合物仍然是治疗实体肿瘤的中流砥柱，它们与针对肿瘤类型选择的分子靶向药物的结合，以及所发现的突变预计将导致它们的使用继续增长。然而，它们的毒性仍然是它们使用和有效性的主要障碍，因此，该项目的目标是开发毒性较低的类似物，其效果与目前的药物一样低。该项目将结合铂(IV)前体药物的稳定和细胞捕获方面的最新发展，以及旨在限制这些前体药物对肿瘤环境的激活的一系列策略。

Platinum complexes continue to be a mainstay in the treatment of solid tumours and their combination with molecularly targeted agents selected for the type of tumour and the mutations identified is expected to lead to continued growth in their use. However, their toxicity remains a major impediment to their use and effectiveness and therefore, this project aims to develop less toxic analogues that are as least as effective as current drugs. This project will combine recent developments in stabilisation and cellular trapping of platinum(IV) pro-drugs with a range of strategies designed to limit activation of these pro-drugs to the tumour environment.